TD-0903 3mg - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.15 [0.01, 4.34]< 10%1 study (1/-)86.1 %some concernnot evaluable moderatecrucial-
deaths 0.15 [0.01, 4.34]< 10%1 study (1/-)86.1 %some concernnot evaluable moderatecrucial-
clinical improvement 3.00 [0.20, 45.25]> 10%1 study (1/-)78.4 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.00 [0.20, 45.25]> 10%1 study (1/-)78.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.08 [0.00, 2.07]< 10%1 study (1/-)93.4 %some concernnot evaluable moderateimportant-

safety endpoints 00

related AE (TRAE) 0.38 [0.01, 13.93]< 10%1 study (1/-)69.6 %some concernnot evaluable moderateimportant-
adverse events 0.04 [0.00, 1.01]< 10%1 study (1/-)97.3 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.